申请人:Geisbert Thomas W.
公开号:US20110201667A1
公开(公告)日:2011-08-18
The present invention provides compositions comprising therapeutic nucleic acids (e.g., interfering RNA such as siRNA) that target Ebola virus (EBOV) gene expression and methods of using such compositions to silence EBOV gene expression. More particularly, the invention provides unmodified and chemically modified interfering RNA which silence EBOV gene expression and methods of use thereof, e.g., for preventing or treating EBOV infections caused by one or more EBOV species such as Zaire EBOV. The invention also provides serum-stable nucleic acid-lipid particles comprising one or more interfering RNA molecules, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. Methods of silencing EBOV gene expression by administering one or more interfering RNA molecules to a mammalian subject are also provided.
本发明提供了包含治疗性核酸(例如干扰RNA,如siRNA)的组合物,这些核酸靶向埃博拉病毒(EBOV)基因表达,并提供使用这些组合物来沉默EBOV基因表达的方法。更具体地,本发明提供了未经修饰和化学修饰的干扰RNA,这些RNA可以沉默EBOV基因表达,并提供了这些方法的使用,例如,用于预防或治疗由一个或多个EBOV种类(如扎伊尔EBOV)引起的EBOV感染。本发明还提供了包含一个或多个干扰RNA分子、一个阳离子脂质和一个非阳离子脂质的血清稳定的核酸脂质颗粒,该颗粒可以进一步包含抑制颗粒聚集的共轭脂质。还提供了通过向哺乳动物主体注射一个或多个干扰RNA分子来沉默EBOV基因表达的方法。